Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Long-Term Debt Repayments (2017 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Long-Term Debt Repayments for 11 consecutive years, with $10.0 million as the latest value for Q1 2025.

  • Quarterly Long-Term Debt Repayments rose 30.33% to $10.0 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $10.0 million through Dec 2025, down 72.12% year-over-year, with the annual reading at $10.0 million for FY2025, 72.12% down from the prior year.
  • Long-Term Debt Repayments hit $10.0 million in Q1 2025 for Cumberland Pharmaceuticals, up from $6.3 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $20.0 million in Q2 2022 to a low of $6.3 million in Q4 2024.
  • Historically, Long-Term Debt Repayments has averaged $11.3 million across 5 years, with a median of $10.9 million in 2023.
  • Biggest five-year swings in Long-Term Debt Repayments: surged 76.47% in 2021 and later tumbled 45.82% in 2023.
  • Year by year, Long-Term Debt Repayments stood at $14.0 million in 2021, then plummeted by 45.0% to $7.7 million in 2022, then rose by 1.8% to $7.8 million in 2023, then dropped by 19.44% to $6.3 million in 2024, then surged by 58.9% to $10.0 million in 2025.
  • Business Quant data shows Long-Term Debt Repayments for CPIX at $10.0 million in Q1 2025, $6.3 million in Q4 2024, and $11.0 million in Q3 2024.